An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008397/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
An open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with
acute myelogenous leukemia (AML), high-grade myelodysplastic syndrome (MDS). The patient
population will consist of adults previously diagnosed with AML including high-grade MDS for
which standard curative, life-prolonging treatment does not exist or is no longer effective.
提供机构：
Vivli
创建时间：
2022-08-29
